Status:
RECRUITING
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Diffuse Large B-Cell Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Eligibility Criteria
Inclusion
- Histologically confirmed R/R DLBCL after one line of systemic therapy
- Will be treated with Glofit-based regimen (known as being recommended and having the intention to be treated with Glofitamab at the time of signing ICF) or have initiated Glofit-based regimen treatment within three months (90 days) prior to enrollment
Exclusion
- Participants who currently participate in or plan to participate in any interventional clinical trial
Key Trial Info
Start Date :
September 29 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 29 2029
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT07200375
Start Date
September 29 2025
End Date
September 29 2029
Last Update
January 7 2026
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese Academy of Medical Sciences Hematology Hospital;Lymphoma Diagnosis and Treatment Center
Tianjin, Tianjin Municipality, China, 301636
2
Peking University Third Hospital
Beijing, China, 100191
3
The First Bethune Hospital of Jilin University
Changchun, China
4
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China, 200025